Desvenlafaxine
- Atc Codes:N06AX23
- CAS Codes:93413-62-8#386750-22-7
- PHARMGKB ID:93413-62-8#386750-22-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Pristiq; USA: Pristiq.
Latin America
Brazil: Pristiq.
Drug combinations
Chemistry
Desvenlafaxine: C~16~H~25~NO~2~ C10H~21~NO~2~. Mw: 263.37. (1) O-desmethylvenlafaxine; (2) R,S-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol. CAS-93413-62-8.
Desvenlafaxine Succinate: C~20~H~33~NO~7~ Mw: 399.48. 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate hydrate. CAS-386750-22-7.
Pharmacologic Category
Antidepressants; Selective Serotonin- and Norepinephrine-reuptake Inhibitors. (ATC-Code: N06AX23).
Mechanism of action
Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The clinical efficacy of desvenlafaxine is thought to be related to the potentiation of these neurotransmitters in the central nervous system.
Therapeutic use
Treatment of major depressive disorder (MDD).
Pregnancy and lactiation implications
Use only if potential benefit to pregnant or breastfeeding women outweighs possible risk to the fetus.
Unlabeled use
Contraindications
Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any excipients in this formulation. Do not use with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping treatment before starting an MAOI.
Warnings and precautions
Monitor for clinical worsening and suicide risk. Serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with SSRIs and SNRIs (desvenlafaxine should be discontinued). Hypertension should be controlled before initiating and during treatment. May increase risk of bleeding events (caution with concomitant use with NSAIDs, aspirin, or other drugs that affect coagulation) and activation of mania/hypomania. Use cautiously in cardio- or cerebrovascular disease and lipid metabolism disorders, since cholesterol and triglyceride elevations have been observed. Drugs containing desvenlafaxine or venlafaxine should not be used concomitantly. Mydriasis, discontinuation symptoms, seizure, hyponatremia in association with SIADH, interstitial lung disease and eosinophilic pneumonia may manifest.